Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type(537 views) Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2008 Aug 15; 14(16): 5209-5219.
Keywords: Aged, Animals, Apoptosis Drug Effects, Blotting, Western, Carcinoma, Non-Small-Cell Lung Drug Therapy Metabolism, Cell Line, Tumor, Female, Humans, Immunoprecipitation, Inositol 1, 5-Trisphosphate Receptors Metabolism, Lung Neoplasms Drug Therapy Metabolism, Membrane Potential, Mitochondrial Drug Effects, Nude, Middle Aged, Mitochondria Drug Effects, Positron-Emission Tomography, Protein Kinase Inhibitors Pharmacology, Proto-Oncogene Proteins C-Bcl-2 Metabolism, Quinazolines Pharmacology, Radiopharmaceuticals Diagnostic Use, Epidermal Growth Factor Drug Effects Metabolism, Signal Transduction Drug Effects Physiology, Technetium Tc 99m Sestamibi Diagnostic Use, Bcl-X Protein Metabolism, Calcium, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Gefitinib, Inositol Trisphosphate, Inositol Trisphosphate Receptor Type 3, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Protein Bcl 2, Unclassified Drug, Diagnostic Agent, 5 Trisphosphate Receptor, Quinazoline Derivative, Radiopharmaceutical Agent, Adult, Animal Experiment, Animal Model, Article, Case Report, Controlled Study, Drug Accumulation, Drug Blood Level, Drug Uptake, Human Cell, In Vivo Study, Lung Cancer, Mouse, Nonhuman, Priority Journal, Protein Expression, Protein Interaction, Protein Phosphorylation, Single Photon Emission Computer Tomography, Lung Non Small Cell Cancer, Lung Tumor, Mitochondrial Membrane Potential, Nude Mouse, Positron Emission Tomography, Tumor Cell Line, Western Blotting, Erlotinib Hydrochloride,
Affiliations: *** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research Council.
Department of Experimental Oncology, National Cancer InstituteNaples, Italy
Department of Endocrinology and Molecular and Clinical OncologyNaples, Italy
Biomorphological and Functional Sciences, University of Naples Federico IINaples, Italy
References: Ono, M., Kuwano, M., Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs (2006) Clin Cancer Res, 12, pp. 7242-725
Herbst, R. S., Fukuoka, M., Baselga, J., Gefitinib-novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Brehmer, D., Greff, Z., Godl, K., Cellular targets of gefitinib (2005) Cancer Res, 65, pp. 379-382
Sun, S., Schiller, J. H., Spinola, M., Minna, J. D., New molec-ularly targeted therapies for lung cancer (2007) J Clin Invest, 117, pp. 2740-2750
Johnson, B. E., Janne, P. A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Res, 65, pp. 7525-7529
Bianco, R., Melisi, D., Ciardiello, F., Tortora, G., Key cancer cell signal transduction pathways as therapeutic targets (2006) Eur J Cancer, 42, pp. 290-294
Lynch, T. J., Bell, D. W., Sordella, R., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139
Paez, J. G., Janne, P. A., Lee, J. C., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500
Engelman, J. A., Janne, P. A., Mermel, C., ErbB-3 mediates phosphoinositide 3-kinase activity in gefiti-nib-sensitive non-small cell lung cancer cell lines (2005) Proc Natl Acad Sci U S A, 102, pp. 3788-3793
Eberhard, D. A., Johnson, B. E., Amler, L. C., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib (2005) J Clin Oncol, 23, pp. 5900-5909
Sordella, R., Bell, D. W., Haber, D. A., Settleman, J., Gefiti-nib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways (2004) Science, 305, pp. 1163-1167
Weinstein, I. B., Cancer. Addiction to oncogenes-the Achilles heal of cancer (2002) Science, 297, pp. 63-64
Costa, D. B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Kuroda, J., Puthalakath, H., Cragg, M. S., Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) Proc Natl Acad Sci USA, 103, pp. 14907-14912
Pao, W., Miller, V. A., Politi, K. A., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain (2005) PLoS Med, 2, pp. e73
Kwak, E. L., Sordella, R., Bell, D. W., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib (2005) Proc Natl Acad Sci U S A, 102, pp. 7665-7670
Kobayashi, S., Boggon, T. J., Dayaram, T., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib (2005) N Engl J Med, 352, pp. 786-792
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316, pp. 1039-1043
Bean, J., Brennan, C., Shih, J. Y., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) Proc Natl Acad Sci U S A, 104, pp. 20932-20937
Deng, J., Shimamura, T., Perera, S., Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion (2007) Cancer Res, 67, pp. 11867-11875
Reed, J. C., Proapoptotic multidomain Bcl-2/Bax- family proteins: Mechanisms, physiological roles, and therapeutic opportunities (2006) Cell Death Differ, 13, pp. 1378-1386
Bassik, M. C., Scorrano, L., Oakes, S. A., Pozzan, T., Korsmeyer, S. J., Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis (2004) EMBO J, 23, pp. 1207-1216
Oakes, S. A., Scorrano, L., Opferman, J. T., Proapoptotic BAX and BAK regulate the type 1 inositol trisphos-phate receptor and calcium leak from the endoplasmic reticulum Proc Natl Acad Sci, USA2005 (102), pp. 105-110
Chen, R., Valencia, I., Zhong, F., Bcl-2 functionally interacts with inositol 1, 4, 5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1, 4, 5-trisphosphate (2004) J Cell Biol, 166, pp. 193-203
Danial, N. N., Korsmeyer, S. J., Cell death: Critical control points (2004) Cell, 116, pp. 205-219
Li, C., Wang, X., Vais, H., Thompson, C. B., Foskett, J. K., White, C., Apoptosis regulation by Bcl-x (L) modulation of mammalian inositol 1, 4, 5-trisphosphate receptor channel isoform gating (2007) Proc Natl Acad Sci USA, 104, pp. 12565-12570
Piwnica-Worms, D., Kronauge, J. F., Chiu, M. L., Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (l) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence (1990) Circulation, 82, pp. 1826-1838
Aloi, L., Zannetti, A., Caraco, C., Del Vecchio, S., Salvatore, M., Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines (2004) Eur J Nucl Med Mol Imaging, 31, pp. 521-527
Del Vecchio, S., Zannetti, A., Aloj, L., Caraco, C., Ciarmiello, A., Salvatore, M., Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma (2003) Eur J Nucl Med Mol Imaging, 30, pp. 879-887
Zannetti, A., Del Vecchio, S., Carriero, M. V., Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma (2000) Cancer Res, 60, pp. 1546-1551
Yang, C. H., Huang, C. J., Yang, C. S., Gefitinib reverses chemotherapy resistance in gefitinib-insensi-tive multidrug resistant cancer cells expressing ATP-binding cassette family protein (2005) Cancer Res, 65, pp. 6943-6949
Elkind, N. B., Szentpetery, Z., Apati, A., Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) (2005) Cancer Res, 65, pp. 1770-1777
Nakamura, Y., Oka, M., Soda, H., Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance (2005) Cancer Res, 65, pp. 1541-1546
Wang, H. G., Pathan, N., Ethell, I. M., Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD (1999) Science, 284, pp. 339-343
Shibasaki, F., Kondo, E., Akagi, T., McKeon, F., Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2 (1997) Nature, 386, pp. 728-731
Gong, Y., Somwar, R., Politi, K., Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas (2007) PLoS Med, 4, pp. e294
White, C., Li, C., Yang, J., The endoplasmic reticulum gateway to apoptosis by Bcl-X (L) modulation of the lnsP3R (2005) Nat Cell Biol, 7, pp. 1021-1028
Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Herbst, R.S., Fukuoka, M., Baselga, J., Gefitinib-novel targeted approach to treating cancer (2004) Nat Rev Cancer, 4, pp. 956-965
Johnson, B.E., Janne, P.A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Res, 65, pp. 7525-7529
Lynch, T.J., Bell, D.W., Sordella, R., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139
Paez, J.G., Janne, P.A., Lee, J.C., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500
Engelman, J.A., Janne, P.A., Mermel, C., ErbB-3 mediates phosphoinositide 3-kinase activity in gefiti-nib-sensitive non-small cell lung cancer cell lines (2005) Proc Natl Acad Sci U S A, 102, pp. 3788-3793
Eberhard, D.A., Johnson, B.E., Amler, L.C., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib (2005) J Clin Oncol, 23, pp. 5900-5909
Weinstein, I.B., Cancer. Addiction to oncogenes-the Achilles heal of cancer (2002) Science, 297, pp. 63-64
Costa, D.B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Kwak, E.L., Sordella, R., Bell, D.W., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib (2005) Proc Natl Acad Sci U S A, 102, pp. 7665-7670
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316, pp. 1039-1043
Reed, J.C., Proapoptotic multidomain Bcl-2/Bax- family proteins: Mechanisms, physiological roles, and therapeutic opportunities (2006) Cell Death Differ, 13, pp. 1378-1386
Bassik, M.C., Scorrano, L., Oakes, S.A., Pozzan, T., Korsmeyer, S.J., Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis (2004) EMBO J, 23, pp. 1207-1216
Oakes, S.A., Scorrano, L., Opferman, J.T., Proapoptotic BAX and BAK regulate the type 1 inositol trisphos-phate receptor and calcium leak from the endoplasmic reticulum Proc Natl Acad Sci, USA2005 (102), pp. 105-110
Danial, N.N., Korsmeyer, S.J., Cell death: Critical control points (2004) Cell, 116, pp. 205-219
Yang, C.H., Huang, C.J., Yang, C.S., Gefitinib reverses chemotherapy resistance in gefitinib-insensi-tive multidrug resistant cancer cells expressing ATP-binding cassette family protein (2005) Cancer Res, 65, pp. 6943-6949
Elkind, N.B., Szentpetery, Z., Apati, A., Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) (2005) Cancer Res, 65, pp. 1770-1777
Wang, H.G., Pathan, N., Ethell, I.M., Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD (1999) Science, 284, pp. 339-343
Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type
Vitiello M, Finamore E, Falanga A, Raieta K, Cantisani M, Galdiero F, Pedone C, Galdiero M, Galdiero S * Fusion in Coq(481 views) Lecture Notes In Computer Science (ISSN: 0302-9743, 0302-974335404636319783540463634, 0302-974335402975459783540297543), 2001; 2178LNCS: 583-596. Impact Factor:0.415 ViewExport to BibTeXExport to EndNote